LENZ Therapeutics, Inc. Financial Ratios
LENZ / Health Care|FY2025 SEC 10-K data
Includes DuPont ROE decomposition, profitability margins, liquidity ratios, solvency indicators, and earnings quality analysis. All ratios calculated from FY2025 SEC 10-K data.
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 4.71 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
DuPont ROE Decomposition (FY2025)
Return on Equity
-28.9%
Profit Margin
-430.3%
Net Income / Revenue
Asset Turnover
0.06
Revenue / Total Assets
Equity Multiplier
1.08
Total Assets / Equity
Composite: -28.9% (reported: -28.9%)
Profitability
Liquidity
Current Ratio
14.23
Quick Ratio
14.09
Solvency
Interest Coverage
-
Efficiency
Asset Turnover
0.06
Inventory Turnover
0.14
Days Sales Outstanding
6 days
As of FY2025 · SEC 10-K · Updated Mar 28, 2026
Earnings Quality
Accrual Ratio
-5.0%
-9.4pp YoY
Earnings are primarily supported by operating cash flow.
This metric is for informational purposes only and does not constitute investment advice. Data sourced from SEC EDGAR filings; updates may be delayed.